Microbicides and HIV prevention: Lessons from the past, looking to the future

Current Opinion in Infectious Diseases

Volumn 23, Issue 1, 2010, Pages 57-63

  Morris, Georgina C ^a   Lacey, Charles J N ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

HIV; Microbicides; Prevention; Protection; Transmission

Indexed keywords

5P12 RANTES PROTEIN CONJUGATE; 6P4 RANTES PROTEIN CONJUGATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE SULFATE; CYANOVIRIN N; DAPIVIRINE; DODECYL SULFATE SODIUM; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GRIFFITHSIN; MABGEL; MARAVIROC; MICROBICIDE; MIV 150; MONOCLONAL ANTIBODY 12G5; MONOCLONAL ANTIBODY 2D7; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY Z13; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NAPHTHALENESULFONIC ACID DERIVATIVE; NONOXINOL 9; PRO 140; PRO 2000; PSC RANTES PROTEIN CONJUGATE; R 515; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAVVY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVAGEL;

CLINICAL TRIAL; COITUS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; VAGINA DISCHARGE;

ANTI-INFECTIVE AGENTS, LOCAL; DRUG DISCOVERY; HIV INFECTIONS; HUMANS;

EID: 74249120424     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328334de6d     Document Type: Review

References (81)

1. UNAIDS. AIDS epidemic update: December 2007. Geneva: UNAIDS 2007.
2. UNAIDS. 2008 report on the global AIDS epidemic. Geneva: UNAIDS; 2008.
3. Myer L, Kuhn L, Stein ZA, et al. Intravaginal practices, bacterial vaginosis and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5:786-794.
4. Vermund SH, Allen KL, Quarraisha AK. HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS 2009; 4:266-273.
5. Auvert B, Talijaard D, Lagarde E, et al. Randomised, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005; 2:e298.
6. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet 2007; 369:657-666.
7. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet 2007; 369:643-656.
8. Kalichman SC, Simbayi LC, Cloete A, et al. Integrated gender-based violence and HIV risk reduction intervention for South African men: results of a quasi-experimental field trial. Prev Sci 2009; 10:260-270.
9. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov 2002; 1:977-985.
10. Buchbinder SP, Mehrota DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomized, placebo-controlled, test of concept trial. Lancet 2008; 372:1881-1893.
11. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV 1 acquisition in herpes simplex virus type 2 seropositive women and men who have sex with men: a randomized double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
12. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
13. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009.[Epub ahead of print].
14. McGowan I. Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect 2008; 84:413-417.
15. Mc Gowan I, Anton P. Rectal microbicides. Curr Opin HIV AIDS 2008; 3:593-598.
16. Klasse PJ, Shattock RJ, Moore JP. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006; 3:e351.
17. Rohan LC, Hillier SL, Dezzuti CS. Preventing the sexual transmission of HIV with topical microbicides: another piece of the equation. J Infect Dis 2007; 196:1285-1287.
18. Alliance for microbicide development R&D database. www.microbicide.org. [Accessed 24 August 2009]
19. Grant RM, Hamer D, Hope T, et al. Wither or whither microbicides? Science 2008; 321:532-534.
20. Garg AB, Nuttall J, Romano J. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 2009; 19:143-150.
21. Balzarini J, Van Damme L Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369:787-797.
22. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for prevention of HIV transmission. N Engl J Med 2008; 359:463-472.
23. MauckC, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception 2001; 64:383-391.
24. Malonza IM, Mirembe F, Nakabiito C, et al. Expanded phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005; 19:2157-2163.
25. El-Sadr WM, Mayer KH, Maslankowski L, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 2006; 20:1109-1116. (Pubitemid 43786098)
26. Schwartz JL, Mauck C, Lai JL, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 2006; 74:133-140.
27. Doh AS, Ngoh N, Roddy RK, et al. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days. Contraception 2007; 76:245-249.
28. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 2002; 360:971-977.
29. Feldblum PJ, Adeiga A, Bakare R, et al. Savvy vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1474.
30. Peterson L, Nanda K, Opoku BF, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2:e1312.
31. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
32. Mbopi-Keou F, TrottierS, Omar R, et al. A randomized, double-blind, placebo-controlled phase II extended safety study of two Invisible Condom formulations in Cameroonian women. Contraception 2009 [Epub ahead of print].
33. Abdool Karim S, Coletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides buffergel and 0.5% Pro 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. In: 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
34. Poynten M, Millwood IY, Falster MO, et al. The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies. AIDS 2009; 23:1245-1254.
35. Van der Wijgert JH, Kilmarx PH, Jones HE, et al. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials. Contraception 2008; 77:122-129.
36. Van der Wijgert JHHM, Morrison CS, Cornelisse PGA, et al. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr 2008; 48:203-210.
37. Vincent KL, Bell BA, Rosenthal SL, et al. Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety. Sex Transm Dis 2008; 35:269-275.
38. Vincent KL, Bourne N, Bell BA, et al. High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis 2009; 36:31 2-31 8.
39. Bollen LJM, Blanchard K, Kilmarx P, et al. No increase in cervical proinflammatory cytokines after carraguard use in a placebo-controlled randomized clinical trial. J Acquir Immune Defic Syndr 2008; 47:253-257.
40. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007; 21:467-476.
41. Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 2008; 59:44-54.
42. Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27-34.
43. Cummins JE Jr, Doncel GF. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis 2009; 36 (3 Suppl):S84-S91.
44. Keller M, Herold B. Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol 2006; 56:356-363.
45. Hillier SL, Moench T, Shattock R, et al. In vitro and in vivo: the story of nonoxynol-9. J Acquir Immune Defic Syndr 2005; 39:1-8.
46. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to HIV-1 transmission. J Infect Dis 2001; 184:418-428.
47. Mesquita PMM, Cheshenko N, Wilson S, et al. Disruption of tight junctions by cellulose sulphate facilitates HIV infection: model of microbicide safety. J Infect Dis 2009; 200:599-608.
48. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257-270.
49. Bouschbacher M, Bomsel M, Verronese E, et al. Early events in HIV transmission through a human reconstructed vaginal mucosa. AIDS 2008; 22:1257-1266.
50. Huskens D, Vermeire K, Profy AT, Scholes D. The candidate sulfonated microbicide, PRO2000, has potential multiple mechanisms of action against HIV-1. Antivir Res 2009; 84:38-47.
51. Lacey C. Unacceptable side effects of a hyperosmolar vaginal microbicide in a phase 1 trial [abstract #B08-527]. In: Microbicides 2008 Conference; 24-27 February 2008; New Delhi, India.
52. Morrow KM, Fava JL, Rosen RK, et al. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J Acquir Immune Defic Syndr 2007; 45:93-101.
53. Mauck CK, Van der Straten A. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides. J Acquir Immune Defic Syndr 2008; 49:64-69.
54. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-471.
55. Mnyani C, McIntyre J. Preventing mother-to-child transmission of HIV. BJOG 2009; 116 (Suppl1):71-76.
56. Fisher M, Benn P, Evans B, et al. UK guideline for the use of postexposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006; 17:81-92.
57. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime risk, clinical outcomes and cost effectiveness. Clin Infect Dis 2009; 48:806-815.
58. Okwundu CI, Okoromah CA. Antiretroviral preexposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2009:CD007189.
59. Fisher M. Preexposure prophylaxis for HIV: it's not as easy as ABC. CurrOpin Infect Dis 2007; 20:1-2.
60. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:416-423.
61. Romano J, Variano B, Copan P, et al. Safety and availability of dapivirine (TMC 120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25:483-488.
62. Vyankandondera J, Rees H, Masenga G, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23:1531-1538.
63. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157.
64. Herrera C, Cranage M, McGowan I, et al. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009; 53:1797-1807.
65. Anton P, Adler A, Khanuknova E, et al. A phase 1 rectal safety and acceptability study of UC781 microbicide gel [abstract #1066]. In: 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8-11 February 2009; Montreal, Canada.
66. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485-487.
67. Cerini F, Landay A, Gichinga C, et al. Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr 2008; 49:472-476.
68. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20:11-18.
69. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19:535-541.
70. Huskens D, Vermeire K, Vandemeulebroucke E, et al. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 2008; 40:2802-2814.
71. O'Keefe BR, Vojdani F, Buffa V, et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 2009; 106:6099-6104.
72. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
73. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16:227-233.
74. Armbruster C, Stiegler GM, Vcelar BA, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004; 54:915-920.
75. Mehandru S, Vcelar B, Wrin T, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007; 81:11016-11031.
76. Vcelar B, Stiegler G, Wolf HM, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161-2170.
77. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-2739.
78. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551.
79. Turville SG, Aravantinou M, Miller T, et al. Efficacy of carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3:e3162.
80. DiClemente RJ, Wingood GM, Blank MB, Metzger DS. Future directions for HIV prevention research charting a prevention science research agenda. J Acquir Immune Defic Syndr 2008; 47:S47-S48.
81. Padian NS, Buve A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008;372:585-599.